Comparison of modified percutaneous transhepatic variceal embolization and endoscopic cyanoacrylate injection for gastric variceal rebleeding

被引:13
作者
Wang, Jing [1 ]
Tian, Xiang-Guo [1 ]
Li, Yan [1 ]
Zhang, Chun-Qing [1 ]
Liu, Fu-Li [1 ]
Cui, Yi [1 ]
Liu, Ji-Yong [1 ]
机构
[1] Shandong Univ, Prov Hosp, Dept Gastroenterol, Jinan 250021, Shandong, Peoples R China
关键词
Gastric varices; Endoscopic variceal obturation; Percutaneous transhepatic variceal embolization; 2-octyl-cyanoacrylate; Bleeding; RETROGRADE TRANSVENOUS OBLITERATION; INTRAHEPATIC PORTOSYSTEMIC SHUNTS; BLEEDING ESOPHAGEAL-VARICES; RANDOMIZED CONTROLLED-TRIAL; TRANS-HEPATIC OBLITERATION; TERM-FOLLOW-UP; PORTAL-HYPERTENSION; N-BUTYL-2-CYANOACRYLATE INJECTION; GASTROESOPHAGEAL VARICES; 2-OCTYL CYANOACRYLATE;
D O I
10.3748/wjg.v19.i5.706
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To compare the efficacy of modified percutaneous transhepatic variceal embolization (PTVE) with 2-octyl-cyanoacrylate (2-OCA) and endoscopic variceal obturation (EVO) with an injection of 2-OCA for prophylaxis of gastric variceal rebleeding. METHODS: In this retrospective study, the medical records of liver cirrhosis patients with gastric variceal bleeding who underwent either endoscopic 2-OCA (EVO) or modified PTVE using 2-OCA at Shandong Provincial Hospital from January 2006 to December 2008 were reviewed. Patient demographics, rebleeding rate, survival rate, and complications were compared between the two groups (PTVE and EVO). All results were expressed as mean +/- SD, or as a percentage. Quantitative variables were compared by two sample Student t tests, and qualitative variables were compared by the Fisher exact test or the chi(2) test (with Yates correction) where appropriate. A P value less than 0.05 was considered significant. Statistical computation was performed using SPSS 13.0 software. RESULTS: A total of 77 patients were included; 45 patients who underwent EVO and 32 patients who received PTVE. During the follow-up (19.78 +/- 7.70 mo in the EVO group, vs 21.53 +/- 8.56 mo in the PTVE group) rebleeding occurred in 17 patients in the EVO group and in 4 patients in the PTVE group (37.78% vs 12.5%, P = 0.028). The cumulative rebleeding-free rate was 75%, 59%, and 49% in 1, 2, and 3 years respectively for EVO, and 93%, 84%, and 84% for PTVE (P = 0.011). Cox analysis was used to identify independent factors that predicted rebleeding after treatment. Variables including age, gender, cause, Child-Pugh classification, size of gastric varices (GV), location of GV, and treatment methods were analyzed. It was revealed that Child-Pugh classification [risk ratio (RR) 2.10, 95% CI: 1.03-4.28, P = 0.040], choice of treatment (RR 0.25, 95% CI: 0.08-0.80, P = 0.019), and size of GV (RR 2.14, 95% CI: 1.07-4.28, P = 0.032) were the independent factors for predicting rebleeding. Follow-up computed tomography revealed that cyanoacrylate was retained in the varices and in the feeding veins of PTVE patients. During the follow-up, eight patients in the EVO group and four patients in the PTVE group died. The cumulative survival rates at 1, 2, and 3 years were 93%, 84%, and 67% respectively in the EVO group, and 97%, 88%, and 74% respectively in the PTVE group. The survival rates were not significantly different between the two groups (P = 0.432). Cox analysis showed that the Child-Pugh classification was the most significant prognostic factor of survival (RR 2.77, 95% CI: 1.12-6.80, P = 0.027). The incidence of complications was similar in both groups. CONCLUSION: With extensive and permanent obliteration of gastric varices and its feeding veins, PTVE with 2-OCA is superior to endoscopic 2-OCA injection for preventing gastric variceal rebleeding. (C) 2013 Baishideng. All rights reserved.
引用
收藏
页码:706 / 714
页数:9
相关论文
共 36 条
[1]   Long-term results of endoscopic Histoacryl injection sclerotherapy for gastric variceal bleeding: A 10-year experience [J].
Akahoshi, T ;
Hashizume, M ;
Shimabukuro, R ;
Tanoue, K ;
Tomikawa, M ;
Okita, K ;
Gotoh, N ;
Konishi, K ;
Tsutsumi, N ;
Sugimachi, K .
SURGERY, 2002, 131 (01) :S176-S181
[2]   Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices [J].
Barange, K ;
Péron, JM ;
Imani, K ;
Otal, P ;
Payen, JL ;
Rousseau, H ;
Pascal, JP ;
Joffre, F ;
Vinel, JP .
HEPATOLOGY, 1999, 30 (05) :1139-1143
[3]   Visceral fistula as a complication of endoscopic treatment of esophageal and gastric varices using isobutyl-2-cyanoacrylate: report of two cases [J].
Battaglia, G ;
Morbin, T ;
Patarnello, E ;
Merkel, C ;
Corona, MC ;
Ancona, E .
GASTROINTESTINAL ENDOSCOPY, 2000, 52 (02) :267-270
[4]   OBLITERATION OF ESOPHAGEAL-VARICES BY PTP - FOLLOW-UP OF 43 PATIENTS [J].
BENGMARK, S ;
BORJESSON, B ;
HOEVELS, J ;
JOELSSON, B ;
LUNDERQUIST, A ;
OWMAN, T .
ANNALS OF SURGERY, 1979, 190 (04) :549-554
[5]   Prevention of variceal rebleeding [J].
Bosch, J ;
García-Pagán, JC .
LANCET, 2003, 361 (9361) :952-954
[6]   Life-threatening pericarditis after N-butyl-2-cyanoacrylate injection for esophageal variceal bleeding: case report [J].
Chen, YY ;
Shen, TC ;
Soon, MS ;
Lai, JH .
GASTROINTESTINAL ENDOSCOPY, 2005, 61 (03) :487-489
[7]  
Cho SK, 2007, AM J ROENTGENOL, V189, pW365, DOI 10.2214/AJR.07.2266
[8]   Pharmacological treatment of portal hypertension: An evidence-based approach [J].
D'Amico, G ;
Pagliaro, L ;
Bosch, J .
SEMINARS IN LIVER DISEASE, 1999, 19 (04) :475-505
[9]   Evolving consensus in portal hypertension - Report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertension [J].
de Franchis, R .
JOURNAL OF HEPATOLOGY, 2005, 43 (01) :167-176
[10]   Prevention and management of Gastroesophageal varices and variceal Hemorrhage in cirrhosis [J].
Garcia-Tsao, Guadalupe ;
Sanyal, Arun J. ;
Grace, Norman D. ;
Carey, William .
HEPATOLOGY, 2007, 46 (03) :922-938